HIA
CRNX icon

HFM Investment Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

HFM Investment Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150 Buy
+4
New +$149 ﹤0.01% 1207

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HFM Investment Advisors's CRNX Position: Q2 2026 in Review

HFM Investment Advisors opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 4 shares worth $150. The stake represents ﹤0.01% of the portfolio and ranks #1207 among its holdings.

266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • HFM Investment Advisors held 4 shares of Crinetics Pharmaceuticals worth $150 as of Q2 2026.
  • Crinetics Pharmaceuticals was a new HFM Investment Advisors position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #1207 holding.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.